The global mesenchymal stem cells (MSC) market size is expected to reach USD 7.27 billion by 2030, expanding at a CAGR of 12.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. An exponential increase in Mesenchymal Stem Cell (MSC) based research and its implications in the field of regenerative medicine is anticipated to fuel the industry expansion. Moreover, the constantly evolving landscape of cell therapies is also anticipated to propel investments in the mesenchymal stem cells market space; large-scale operational firms are targeting small or emerging players with an operating strategy of acquisition to bolster their market presence.

The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the industry growth. For instance, in 2022, the U.S.FDA has approved around 19 stem cell therapies for range of life-threatening disorders. Some of these therapies include, BREYANZI of BMS, ALLOCORD, KYMIRAH of Novartis etc. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutic regime for the management of inflammatory conditions, in turn, boosting market growth.

For instance, on January 2022, the Century Therapeutics and Bristol Myers Squibb entered a collaboration to expand IPSC-derives allogenic cell therapies. In addition, Takeda/TiGenix phase 3 clinical trial incorporated mesenchymal stem cells for complex perianal fistulas in Crohn's Disease. This was the most successful late-stage clinical trial as of September 2020. In addition, in August 2022 AGC Biologics partnered with human mesenchymal stem cell supplier, RoosterBio Inc. to deliver clinically proven advanced therapies for life-threatening conditions. These factors are projected to bolster the usage of stem cell products offered by key entities, thereby intensifying the market competition.

Gather more insights about the market drivers, restrains and growth of the Mesenchymal Stem Cells Market

Mesenchymal Stem Cells Market Report Highlights

• The products segment dominated the segment and accounted for the largest revenue share of 78.89% in 2023. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue

• Based on workflow type, the culture and cryopreservation segment dominated the industry with revenue share of 44.55% in 2023. The segment growth is attributed to the high demand for cryopreservation services and enhancement of healthcare infrastructure in developing economies

• The allogenic MSCs segment accounted for the higher revenue share of 56.60% in 2023. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications

• The bone marrow segment dominated the market and accounted for the largest revenue share of 24.56% in 2023. Bone marrow is a major source of isolation for mesenchymal cells

• The disease modelling application segment dominated the application and accounted for the largest revenue share of 35.23% in 2023. The use of cellular disease models with patient specific MSCs provides an ideal tool for pathological research

• North America dominated the market and accounted for the largest revenue share of 45.11% in 2023. The higher revenue share of the region is accounted to supportive government legislation and rising application of cell therapies in chronic disorders

Mesenchymal Stem Cells Market Segmentation

Grand View Research has segmented the global mesenchymal stem cells market based on Product & services, workflow type, type,source of isolation,indication, application and region:

Mesenchymal Stem Cells Products & Services Outlook (Revenue, USD Million, 2018 - 2030)

• Products

o Cells & Cell Lines

o Kits, Media, & Reagents

o Others

• Services

Mesenchymal Stem Cells Workflow Type Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Sourcing & Isolation

• Culture & Cryopreservation

• Differentiation

• Characterization

Mesenchymal Stem Cells Type Outlook (Revenue, USD Million, 2018 - 2030)

• Autologous

• Allogenic

Mesenchymal Stem Cells Source of Isolation Outlook (Revenue, USD Million, 2018 - 2030)

• Bone Marrow

• Cord Blood

• Peripheral Blood

• Fallopian Tube

• Fetal Liver

• Lung

• Adipose Tissues

Mesenchymal Stem Cells Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Bone And Cartilage Repair

• Cardiovascular Diseases

• Inflammatory And Immunological Diseases

• Liver Diseases

• Cancer

• GvHD

• Others

Mesenchymal Stem Cells Application Outlook (Revenue, USD Million, 2018 - 2030)

• Disease Modeling

• Drug Development & Discovery

• Stem Cell Banking

• Tissue Engineering

• Toxicology Studies

• Others

Mesenchymal Stem Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Mesenchymal Stem Cells Market Intelligence Study, published by Grand View Research.